Drugdocs | Lokelma

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Lokelma

Chemical Name	sodium zirconium cyclosilicate
Dosage Form	Suspension (oral; 5 g, 10 g)
Drug Class	Potassium binders
System	Blood
Company	AstraZeneca
Approval Year	2018

Indication

Lokelma is indicated for the treatment of hyperkalemia in adults.

Last updated on 6/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Lokelma (sodium zirconium cyclosilicate) Prescribing Information	2018	AstraZeneca

Document Title	Year	Source
Clinical review report: sodium zirconium cyclosilicate (lokelma).	2020	CADTH
Pharmacoeconomic review: sodium zirconium cyclosilicate (lokelma).	2020	CADTH
Sodium zirconium cyclosilicate for treating hyperkalaemia.	2019	NICE
Lokelma: EPAR – public assessment report.	2018	EMA

Document Title	Year	Source
Systematic review and meta-analysis of patiromer and sodium zirconium cyclosilicate: A new armamentarium for the treatment of hyperkalemia.	2017	Pharmacotherapy

Document Title	Year	Source
Clinical practice guidelines: treatment of acute hyperkalaemia in adults.	2019	The Renal Association